Anika Therapeutics, Inc.
corporate_fare Company Profile
Anika Therapeutics, Inc. (NASDAQ:ANIK) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 16 items for ANIK at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 8/10, with 6 rated 8 or above. Recent SEC coverage for ANIK spans 10-Q, 8-K, DEFA14A, DEF 14A.
Recent high-impact activity:
- Anika 10-Q: Q3 Revenue $30.6M; FDA Deems Hyalofast PMA Not Approvable
- Anika Lifts Low End of Full-Year Revenue Guidance
- Anika Beats on Revenue Growth, Raises EBITDA Outlook Despite Hyalofast FDA Rejection
- Anika Therapeutics Swings to Q2 Profit on 16% Revenue Jump, Margin Expansion
- Record Q2 propels Anika Therapeutics to raise 2026 guidance
Financial Snapshot
Short Interest & Short Volume
3.13 days to coverFINRA reported short interest of 323,508 shares in ANIK as of the October 30, 2026 settlement, a 11.5% decrease from the prior period — about 3.1 days to cover at its recent average daily volume. On November 20, 2026, 58.6% of ANIK volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.